Document Detail

Eptifibatide: The evidence for its role in the management of acute coronary syndromes.
MedLine Citation:
PMID:  20694065     Owner:  NLM     Status:  PubMed-not-MEDLINE    
INTRODUCTION: Acute coronary syndromes and non-Q-wave myocardial infarction are often initiated by platelet activation. Eptifibatide is a cyclic heptapeptide and is the third inhibitor of glycoprotein (Gp) IIb/IIIa that has found broad acceptance after the specific antibody abciximab and the nonpeptide tirofiban entered the global market. Gp IIb/IIIa inhibitors act by inhibiting the final common pathway of platelet aggregation, and play an important role in the management of acute coronary syndromes.
AIMS: This review assesses the evidence for therapeutic value of eptifibatide as a Gp IIb/IIIa inhibitor in patients with acute coronary syndromes.
EVIDENCE REVIEW: Several large, randomized controlled trials show that eptifibatide as adjunctive therapy to standard care in patients with non-ST segment elevation acute coronary syndrome is associated with a significant reduction in the incidence of death or myocardial infarction. Data are limited regarding the use of eptifibatide in patients with ST segment elevation myocardial infarction. Cost-effectiveness analysis indicates that eptifibatide is associated with a favorable cost-effectiveness ratio relative to standard care. According to US cost-effectiveness analysis about 70% of the acquisition costs of eptifibatide are offset by the reduced medical resource consumption during the first year. Eptifibatide was well tolerated in most of the trials. Bleeding is the most commonly reported adverse event, with most major bleeding episodes occurring at the vascular access site. Major intracranial bleeds, stroke, or profound thrombocytopenia rarely occurred during eptifibatide treatment.
PLACE IN THERAPY: Eptifibatide has gained widespread acceptance as an adjunct to standard anticoagulation therapy in patients with acute coronary syndromes, and may be particularly useful in the management of patients with elevated troponin or undergoing percutaneous coronary interventions.
Ibrahim Shah; Shakeel O Khan; Surender Malhotra; Tim Fischell
Related Documents :
18340145 - Risk stratification and the management of non-st-segment elevation acute coronary syndr...
10874265 - Reduction in the need for hospitalization for recurrent ischemic events and bleeding wi...
16168275 - Aspirin use in older patients with heart failure and coronary artery disease: national ...
9727545 - Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a d...
9138835 - Diagnostic accuracy of dipyridamole technetium 99m-labeled sestamibi myocardial tomogra...
12025955 - Myxoma attached to both atrial and ventricular sides of the mitral valve: report of a c...
Publication Detail:
Type:  Journal Article     Date:  2010-06-15
Journal Detail:
Title:  Core evidence     Volume:  4     ISSN:  1555-175X     ISO Abbreviation:  Core Evid     Publication Date:  2009  
Date Detail:
Created Date:  2010-08-09     Completed Date:  2011-07-14     Revised Date:  2014-06-02    
Medline Journal Info:
Nlm Unique ID:  101256593     Medline TA:  Core Evid     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  49-65     Citation Subset:  -    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Erratum In:
Core Evid. 2014;9:49

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Axitinib: The evidence of its potential in the treatment of advanced thyroid cancer.
Next Document:  Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy.